- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Millbrae Today
By the People, for the People
Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Provides Clinical Updates
Biopharmaceutical company highlights progress on pipeline, including Phase 2 lung cancer study and new PARP inhibitor trials.
Mar. 30, 2026 at 12:13pm
Got story updates? Submit your updates here. ›
Eikon Therapeutics' innovative cancer drug pipeline represents the company's commitment to scientific advancement and delivering breakthrough treatments.Millbrae TodayEikon Therapeutics, a late-stage clinical biopharmaceutical company, announced its fourth quarter and full year 2025 financial results and provided updates on its clinical programs. The company highlighted progress in advancing multiple registration-enabling programs, including the Phase 2 TeLuRide-005 study evaluating its lead candidate EIK1001 in non-small cell lung cancer, as well as the initiation of new Phase 1/2 trials for its next-generation PARP inhibitors EIK1003 and EIK1004.
Why it matters
Eikon's pipeline of innovative cancer therapies targeting serious unmet medical needs represents an important area of focus as the company works to deliver breakthrough treatments to patients. The progress on its clinical programs, along with the strengthening of its balance sheet through a recent IPO, position Eikon to continue advancing its mission of developing impactful new medicines.
The details
Key updates from Eikon's pipeline include the completed enrollment in the TeLuRide-005 Phase 2 study evaluating EIK1001, a dual-agonist of Toll-like receptors 7 and 8, in combination with pembrolizumab and chemotherapy for first-line non-small cell lung cancer treatment. The company also highlighted the ongoing Phase 1/2 trials for its highly-selective PARP inhibitors EIK1003 and EIK1004, including the planned initiation of a combination cohort with platinum and paclitaxel therapy in breast and ovarian cancer. Additionally, Eikon reported the successful completion of a healthy volunteer study for its WRN helicase inhibitor EIK1005, allowing for the initiation of a Phase 1/2 trial in patients with malignant disease.
- Enrollment was completed in the TeLuRide-005 Phase 2 study evaluating EIK1001 in 2025.
- Initiation of Cohort 1D, combining EIK1003 with platinum and paclitaxel therapy, is anticipated in the second half of 2026.
- Successful completion of a healthy volunteer study for EIK1005 occurred by the end of 2025, enabling the initiation of a Phase 1/2 trial.
The players
Roger M. Perlmutter, M.D., Ph.D.
Chief Executive Officer and Board Chair of Eikon Therapeutics.
David W. Meline
Independent director of Eikon Therapeutics, former Chief Financial Officer at Moderna Inc. and Amgen Inc.
What they’re saying
“2025 was an important year of progress for Eikon's business and clinical programs.”
— Roger M. Perlmutter, M.D., Ph.D., Chief Executive Officer and Board Chair
What’s next
The company expects a comprehensive data set from the TeLuRide-005 Phase 2 study to become available in the second half of 2026.
The takeaway
Eikon's advancements in its clinical pipeline, including the progress of its lead candidate EIK1001 and next-generation PARP inhibitors, combined with the strengthening of its balance sheet through a recent IPO, position the company to continue driving innovation in cancer therapeutics and delivering on its mission of developing breakthrough treatments for patients.